# Respiratory Syncytial Virus (RSV) Vaccine Safety Monitoring

**Table of content:**
- [27OCT23](#27OCT23)

<a id="27OCT23"></a>  
On data lock point of 27 Oct 2023, the [Safety Competitive Analysis Arexvy vs Abrysvo](https://ospv.github.io/RSV/2023_10_27%20-%20Safety%20Competitive%20Analysis%20-%20Arexvy%20vs%20Abrysvo.html) report highlighted the following quantitative signals for Arexvy (GSK) and Abrysvo (Pfizer):  

| Arexvy | Abrysvo |
|--------|---------|
| [Exposure during pregnancy](https://ospv.github.io/RSV/2023_10_27_SignalEval_Pregnancy_exposure.html) | [Incorrect route of product administration](https://ospv.github.io/RSV/2023_10_27%20-%20Incorrect%20route%20of%20product%20administration%20post%20Abrysvo.html) |
| [Product preparation issue](https://ospv.github.io/RSV/2023_10_27%20-%20Product%20preparation%20issue%20post%20Arexvy.html) | |
| [Product use issue](https://ospv.github.io/RSV/2023_10_27%20-%20Product%20use%20issue%20post%20Arexvy.html) | |
| [Peripheral swelling](https://ospv.github.io/RSV/2023_10_27%20-%20Peripheral%20swelling%20post%20Arexvy.html) |
| [Rash](https://ospv.github.io/RSV/2023_10_27%20-%20Rash%20post%20Arexvy.html) |
 
